ANI Pharmaceuticals (ANIP) Leerink Global Healthcare Conference 2025 summary

Business segment overview

• Operates in three segments: rare disease, generics, and brands, each contributing to growth and profitability.

• 2025 guidance: $756–$776 million in revenue, $190–$200 million in adjusted non-GAAP EBITDA, and $6.12–$6.49 in adjusted non-GAAP EPS.

• Rare disease segment, led by Purified Cortrophin Gel, is expected to account for nearly half of 2025 revenues.

• Generics business has delivered low double-digit growth for three years, with similar growth expected in 2025.

• Brands portfolio generates high margins and strong cash flow, supporting investments in rare disease growth.

Drivers of raised 2025 guidance

• Strong momentum in Purified Cortrophin Gel sales, aided by early positive impact from IRA and faster-than-expected sales force expansion.

• Successful launch of first-to-file generic prucalopride, showing robust early performance.

• Increased demand in the brands portfolio observed in Q4 and continuing into Q1.

Purified Cortrophin Gel growth outlook

• 2025 sales guidance for Purified Cortrophin Gel: $265–$274 million, representing over 35% growth.

• Growth supported by strong new patient starts, expansion into multiple therapeutic areas, and significant market headroom.

• 40% of prescribers are new to ACTH therapy, indicating expanding reach.

• Unique acute gouty arthritis indication serves as a gateway for broader usage.

• Prefilled syringe presentation approved ahead of schedule, expected to enhance patient convenience.